Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer
Cisplatin is a standard of care for lung cancer, yet platinum therapy rarely results in substantial tumor regression or a dramatic extension in patient survival. Here, we examined whether targeting Rev7 (also referred to as Mad2B, Mad2L2, and FANCV), a component of the translesion synthesis (TLS) ma...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Proceedings of the National Academy of Sciences
2021
|
| Online Access: | https://hdl.handle.net/1721.1/134118 |